Key result
Cardiac contractility modulation therapy improved right ventricular systolic function at 6 months, increasing TAPSE from 16.6 to 18.5 mm (p < 0.05).
Why the study?
Little evidence was available regarding the effects of cardiac contractility modulation on right ventricular function and right ventricular-pulmonary artery coupling.
Does cardiac contractility modulation therapy improve right ventricular function and RV-pulmonary artery coupling in patients with HFrEF?
Comparison
CCM therapy pre- vs post-treatment
Design
Echocardiographic observational study
Follow-up
six months
Authors
Loading...
May support CCM for RV function in HFrEF; hypothesis-generating from cohort data, RCTs needed.
Observational (n=21)
Does cardiac contractility modulation therapy improve right ventricular function and RV-pulmonary artery coupling in patients with HFrEF?
Absolute Event Rate: 18.5% vs 16.6%
p-value: p=< 0.05
Cardiac contractility modulation therapy is associated with significant improvements in right ventricular systolic function and RV-pulmonary artery coupling at 6 months in patients with HFrEF.
Contaldi et al. (2022) conducted an observational in Heart failure with reduced and mild reduced ejection fraction (HFrEF/HFmrEF) (n=21). Cardiac contractility modulation (CCM) vs. Baseline was evaluated on Tricuspid annular systolic excursion (TAPSE) (p=< 0.05). Cardiac contractility modulation therapy improved right ventricular systolic function at 6 months, increasing TAPSE from 16.6 to 18.5 mm (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: